InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
IPO Year: 2019
Exchange: NASDAQ
Website: inmodemd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/17/2024 | $25.00 | Buy | BTIG Research |
| 7/23/2024 | $21.00 → $19.00 | Buy → Hold | Jefferies |
| 11/3/2023 | $52.00 → $24.00 | Buy → Neutral | UBS |
| 10/13/2023 | $55.00 → $22.00 | Buy → Hold | Canaccord Genuity |
| 3/29/2023 | $40.00 | Buy | UBS |
| 2/17/2023 | Buy → Hold | Needham | |
| 12/21/2022 | $44.00 | Overweight | Barclays |
| 10/12/2022 | $40.00 | Buy | Jefferies |
| 2/11/2022 | $103.00 → $82.00 | Buy | Needham |
| 10/27/2021 | $80.00 → $100.00 | Buy | Canaccord Genuity |
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
Quarterly GAAP revenues of $97.9 million and full year revenue of $394.8 million Returned $285.4 million of capital to shareholders in full year 2024 Together with new 10% program, represents repurchase of approximately 27% of shares outstanding within 15 month timeframe, with the potential of substantial additional capital return in 2025 YOKNEAM, Israel, Feb. 4, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year 2024. F
YOKNEAM, Israel, Feb. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference in Snowbird, UT on Wednesday, February 12, 2025. Interested investors are welcome to contact their BTIG salesperson and schedule a meeting. For more information about the event, visit InMode's investor relations site here. About InMode InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF"
Conference call rescheduled to Tuesday, February 4, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 16, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it has adjusted the date for its fourth quarter and full year 2024 earnings conference call to an earlier date. Originally scheduled for Thursday, February 6, the call will now be held on Tuesday, February 4, 2025, at 8:30 am Eastern Standard Time. The company plans to release its financial results before the Nasdaq market opens that same day. InMode will host a conference call to discuss the fourth quarter and full year 2024 financial results
Believes the Board Must Immediately Execute a Tender Offer for 30% of the Company Lays Out Action Plan to Restore Investor Confidence, Including an additional 10% Share Buyback in 2025 Announces Intent to Fight for Shareholders Should InMode Not Take Appropriate Action MIAMI, Jan. 15, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode") today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to accelerate and increase its stock repurchase. The letter can be downloaded here T
Conference call to be held on Thursday, February 6, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 8, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year 2024 before the Nasdaq market opens on Thursday, February 6, 2025. InMode is currently finalizing its financial results for the fourth quarter and full year of 2024. Management believes that preliminary results reflect stronger-than-expected headwinds in the aesthetics industry, further intensified by broader macroeconomic challenges. While complete financial inform
YOKNEAM, Israel, Nov. 6, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in November and December: UBS Global Healthcare ConferencePresenters: Yair Malca, Chief Financial OfficerFormat: In-person fireside chat moderated by Danielle Antalffy, Senior Equity Analyst, and one-on-one meetingsLocation: Palos Verdes, CAWhen: Tuesday, Nov. 12 at 2:00 pm PTA live webcast of the presentation can be accessed here. Jefferies London Healthcare ConferencePresenters: Moshe Mizrahy, Chief Executive OfficerFormat: In-person fireside chat moderated by Matt Taylor, Senior Equit
YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights: Quarterly GAAP revenue of $130.2 million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024).Quarterly revenues from consumables and service of $15.8 million, a decrease of 11% compared to the third quarter of 2023.GAAP operation income of $48.2 million, *non-GAAP operation income of $52.2 million.Total cash position of $684.9 million as of September 30, 2024
IRVINE, Calif., Oct. 24, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has been granted a preliminary injunction by the U.S. District Court for the Central District of California in a lawsuit filed against sellers identified to be the source of unlawful counterfeit sales of Morpheus8 radiofrequency devices and cartridge accessories. On September 3, 2024, the Honorable Michael Fitzgerald of the U.S. District Court for the Central District of California issued the order granting InMode's motion for a preliminary in
Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2024 before the Nasdaq market opens on Wednesday, October 30, 2024. InMode is
YOKNEAM, Israel, Oct. 1, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies today announced the departure of Shakil Lakhani, President of North America effective September 30, 2024. His departure follows that of Dr. Spero Theodorou, Chief Medical Officer, and Dan Wilson, VP of Sales USA. In addition to the departure of the three executives from InMode's North American operations, over the last few months, InMode has changed the management teams in three of its subsidiaries in Europe: InMode UK, InMode Iberia and InMode
Quarterly GAAP revenues of $97.9 million and full year revenue of $394.8 million Returned $285.4 million of capital to shareholders in full year 2024 Together with new 10% program, represents repurchase of approximately 27% of shares outstanding within 15 month timeframe, with the potential of substantial additional capital return in 2025 YOKNEAM, Israel, Feb. 4, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year 2024. F
Conference call rescheduled to Tuesday, February 4, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 16, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it has adjusted the date for its fourth quarter and full year 2024 earnings conference call to an earlier date. Originally scheduled for Thursday, February 6, the call will now be held on Tuesday, February 4, 2025, at 8:30 am Eastern Standard Time. The company plans to release its financial results before the Nasdaq market opens that same day. InMode will host a conference call to discuss the fourth quarter and full year 2024 financial results
Believes the Board Must Immediately Execute a Tender Offer for 30% of the Company Lays Out Action Plan to Restore Investor Confidence, Including an additional 10% Share Buyback in 2025 Announces Intent to Fight for Shareholders Should InMode Not Take Appropriate Action MIAMI, Jan. 15, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode") today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to accelerate and increase its stock repurchase. The letter can be downloaded here T
Conference call to be held on Thursday, February 6, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 8, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year 2024 before the Nasdaq market opens on Thursday, February 6, 2025. InMode is currently finalizing its financial results for the fourth quarter and full year of 2024. Management believes that preliminary results reflect stronger-than-expected headwinds in the aesthetics industry, further intensified by broader macroeconomic challenges. While complete financial inform
YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights: Quarterly GAAP revenue of $130.2 million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024).Quarterly revenues from consumables and service of $15.8 million, a decrease of 11% compared to the third quarter of 2023.GAAP operation income of $48.2 million, *non-GAAP operation income of $52.2 million.Total cash position of $684.9 million as of September 30, 2024
Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2024 before the Nasdaq market opens on Wednesday, October 30, 2024. InMode is
YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Quarterly GAAP revenue of $86.4 million, a decrease of 36.5% compared to the second quarter of 2023. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 87% of its quarterly revenues, while 6% were derived from InMode's traditional laser and non-invasive RF platforms and 7% were derived from InMode's hands-free platforms. Pro-forma revenue (includin
Believes InMode's Cash Balance of Roughly 55% of its Market Cap is Grossly Inefficient Asserts the Current Valuation Offers an Unprecedented Opportunity to Create Shareholder Return MIAMI, July 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of InMode (NYSE: INMD) urging the Board to execute a 40% tender offer of the stock. The letter can be downloaded here. The full text of the letter follows: July 25, 2024 To the Board Members of InMode: DOMA Perpetual Capital Management is an asset manager focused on generating l
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance to $430M-$440M Conference call to be held on Thursday, Aug. 1, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 11, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2024 before the Nasdaq market opens on Thursday, Aug. 1, 2024. InMode is currently finalizing its financial res
Company Announces Share Repurchase Program of Up to 8.37 Million Shares; and Appoints New Chairman of the Board of Directors YOKNEAM, Israel, May 2, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights: Quarterly GAAP revenue of $80.3 million, a decrease of 24% compared to the first quarter of 2023. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 84% of its quarterly revenues, while 11% were derived from InMode's traditiona
6-K/A - InMode Ltd. (0001742692) (Filer)
S-8 - InMode Ltd. (0001742692) (Filer)
20-F - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
SCHEDULE 13D - InMode Ltd. (0001742692) (Subject)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00
Jefferies downgraded InMode from Buy to Hold and set a new price target of $19.00 from $21.00 previously
UBS downgraded InMode from Buy to Neutral and set a new price target of $24.00 from $52.00 previously
Canaccord Genuity downgraded InMode from Buy to Hold and set a new price target of $22.00 from $55.00 previously
UBS initiated coverage of InMode with a rating of Buy and set a new price target of $40.00
Needham downgraded InMode from Buy to Hold
Barclays initiated coverage of InMode with a rating of Overweight and set a new price target of $44.00
Jefferies initiated coverage of InMode with a rating of Buy and set a new price target of $40.00
Needham reiterated coverage of InMode with a rating of Buy and set a new price target of $82.00 from $103.00 previously
Canaccord Genuity reiterated coverage of InMode with a rating of Buy and set a new price target of $100.00 from $80.00 previously